Home
GeniusMed

Business Model

Business

Bio AI smart glasses R&D, plus bio and medical device sales and trade.

Pillar 1

Bio & medical device sales and trade

Our current primary revenue base, generating income immediately.

  • Domestic and overseas distribution of IVD diagnostic products
  • Biopharma and medical-device import/export trade
  • Leveraging partner channels in China, Japan and Singapore
Pillar 2

Bio AI & smart device R&D

Licensing and productisation in the mid term; recurring SaaS and platform subscriptions in the long term.

  • Productisation of AI smart glasses and ECG patches for B2B/B2C sales
  • Licensing of drowsiness accident-prevention technology across automotive, aviation, maritime and industrial sites
  • Bio AI disease-diagnosis SaaS subscription model
  • AI agent platform API provision

Revenue Horizon

Revenue Horizon

01

Short term

Medical device trade and sales revenue

02

Mid term

Technology licensing and productisation

03

Long term

Recurring SaaS and platform subscriptions

Market Opportunity

Market Opportunity

Entering the global IVD, smart glasses and autonomous-driving convergence markets.

$113B+

Global IVD market

~6% CAGR, 2028E

$52B+

Smart glasses market

~25% CAGR, 2030E

$550B+

Autonomous driving market

~35% CAGR, 2030E

0 100 200 300 400 500 600 85 IVD 2024 113 IVD 2028E 10 Smart glasses 2024 52 Smart glasses 2030E 550 Autonomy 2030E MARKET SIZE COMPARISON — UNIT: US$ BILLION
15 MILLION 2025 90 MILLION 2030E 289 MILLION 2035E PROJECTED SMART-GLASSES USERS Source: HSBC Global Research · Omdia

Massive smart-glasses investment by Meta, Samsung, Google and Apple

Deregulation of autonomous driving driving surging demand

AI advances expanding non-invasive medical diagnostics

Aging societies fuelling demand for early chronic-disease diagnosis

Tens of thousands of drowsy-driving casualties a year demand prevention

PCT filings secure a route into the US, EU, China, Japan and India

Growth Roadmap

Growth Roadmap

2026

IP rights & global collaboration

  • Full patent filing for Bio AI diagnosis & AI agents
  • Joint Eurostars proposal with CSEM
  • Recruiting core talent
2027

Prototype & clinical validation

  • Target 95% AI diagnostic accuracy
  • First-generation integrated device prototype and medical-data AI
  • Clinical validation at SNU Bundang Hospital, Severance Hospital and Mayo Clinic
2028+

Global commercialization

  • PCT-based entry into the US, EU, China, Japan and India
  • Ramp-up of approvals, SaaS and licensing revenue
  • Groundwork for a technology-track IPO

Investment Proposal

Shape the future of healthcare and mobility with GeniusMed

Proprietary patents, a global partner network, a hybrid revenue model and entry into massive markets — four axes of growth.

Investor Enquiry Learn More

Patents Filed

6 + 6 PCT

Global Partners

10+

Business

Trade · License · SaaS

Investors

IVD · AR · Autonomy